[HTML][HTML] 704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer
J Adamik, A Grant, D Trujillo, RK Goyal, W Ho… - 2023 - jitc.bmj.com
Background FLX475 is a potent and selective CCR4 antagonist, designed to block
immunosuppressive regulatory T cell (T reg) migration into the tumor microenvironment …
immunosuppressive regulatory T cell (T reg) migration into the tumor microenvironment …
Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048
Background: Cetuximab plus platinum and 5-fluorouracil (5-FU) is the only category 1
evidence-supported combination regimen recommended by current guidelines as first-line …
evidence-supported combination regimen recommended by current guidelines as first-line …
Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from …
LBA6008 Background: Pembrolizumab (MK-3475) is a humanized monoclonal antibody that
blocks interaction of PD-1 with its ligands, PD-L1 and PD-L2, thereby promoting activity of …
blocks interaction of PD-1 with its ligands, PD-L1 and PD-L2, thereby promoting activity of …
KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who …
TPS3094 Background: Treatment options are limited for pts with recurrent and/or metastatic
HNSCC whose disease has progressed after platinum and cetuximab therapy …
HNSCC whose disease has progressed after platinum and cetuximab therapy …
854O INTERLINK-1: Phase III study of cetuximab (CTX)±monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M …
J Fayette, LFL Licitra, KJ Harrington… - Annals of …, 2023 - annalsofoncology.org
Background First-line (1L) treatment for R/M HNSCC includes ICI+/-CT or CT+ CTX.
Treatment after 1L failure is not clearly defined. Preliminary data suggest M (anti-NKG2A)+ …
Treatment after 1L failure is not clearly defined. Preliminary data suggest M (anti-NKG2A)+ …
Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055
R Haddad, T Seiwert, DG Pfister, F Worden… - Annals of …, 2016 - annalsofoncology.org
Background There are few treatment options in recurrent/metastatic (R/M) HNSCC after
progression on platinum and cetuximab, and their efficacy is disappointing. During …
progression on platinum and cetuximab, and their efficacy is disappointing. During …
Abstract LB-258: efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score< 1, 1-19, and≥ 20 in recurrent and/or metastatic (R/M) head and neck …
Introduction: In the phase 3 KEYNOTE-048 trial (NCT02358031) in R/M HNSCC, first-line
pembrolizumab (P) monotherapy vs EXTREME (E; chemotherapy [C]+ cetuximab) improved …
pembrolizumab (P) monotherapy vs EXTREME (E; chemotherapy [C]+ cetuximab) improved …
Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.
JD Powderly, B Chmielowski, JR Brahmer… - 2020 - ascopubs.org
TPS3163 Background: Regulatory T cells (Treg) can dampen anti-tumor immune responses
in the tumor microenvironment (TME). The predominant chemokine receptor on human Treg …
in the tumor microenvironment (TME). The predominant chemokine receptor on human Treg …
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on …
D Adkins, PJ Oppelt, JC Ley, PC Myneni, VR Gogula… - 2023 - ascopubs.org
TPS6108 Background: HNSCC is the seventh most common cancer worldwide. Patients
with R/M disease have limited treatment options and a poor prognosis. The USFDA has …
with R/M disease have limited treatment options and a poor prognosis. The USFDA has …
FDA approval summary: Pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after …
E Larkins, GM Blumenthal, W Yuan, K He… - The …, 2017 - academic.oup.com
Abstract On August 5, 2016, the US Food and Drug Administration granted accelerated
approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp., Kenilworth …
approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp., Kenilworth …